148 results about "Prostate hyperplasia" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to an umbilical cord mesenchymal stem cell preparation and application thereof in treating prostate diseases. According to the umbilical cord mesenchymal stem cell preparation, the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide serve as active components, pharmaceutically acceptable auxiliary materials are matched, the prostate index can be remarkably reduced, the concentration of PACP and SRD5A2 can be reduced, and the umbilical cord mesenchymal stem cell preparation has a remarkable curative effect on prostatic hyperplasia. And the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide supplement each other and have a synergistic effect, so that a remarkable progress is generated.

The invention relates to an AI image navigation method, device and equipment for prostatic hyperplasia minimally invasive surgery and a medium thereof. The method comprises the following steps: acquiring a prostate three-dimensional image and an intraoperative real-time image sequence, and fusing the three-dimensional image after preliminary filtering to obtain an optimized and enhanced image; based on the enhanced image and the preoperative three-dimensional image, a three-dimensional offset vector is obtained through a multi-modal registration algorithm combined with an anatomical structure reference, and optimized prostate three-dimensional attitude data is generated in combination with anatomical constraints; combining the attitude data and the three-dimensional image, determining boundary area distribution characteristics, calculating a risk assessment value, mapping a risk level, and generating a path correction instruction to obtain an instrument navigation path if the risk level exceeds a threshold value; and based on the navigation path, constructing a clinical recovery model in combination with the anatomical structure, generating postoperative recovery index simulation data, and performing adjustment and verification until preset requirements are met to obtain a final operation execution scheme. According to the method, precision and individuation of surgical navigation are achieved, and comprehensive technical support is provided for precise implementation of minimally invasive surgery.

The invention provides application of Fe3O4 nanoparticles in preparation of a medicine for treating benign prostatic hyperplasia, and relates to the technical field of biological medicines. The invention further discloses application of the Fe3O4 nano-particles in preparation of a medicine for treating benign prostatic hyperplasia. The research result of the invention emphasizes that the ferroferric oxide nanoparticles are a promising candidate drug for targeted therapy of BPH and related prostate diseases, and new possibility is provided for treatment intervention of urinary surgery. The inventor studies the effect of the Fe3O4 nanoparticles in inhibiting benign prostatic hyperplasia. Results of the inventor show that the nanoparticles not only effectively reduce the proliferation rate of prostate cells, but also improve related biochemical indexes. Therefore, the polypeptide has potential application in treatment of prostatic hyperplasia.

The invention belongs to the technical field of medical robots and minimally invasive surgery, and provides a robot control system and method for blue laser vaporization surgery of prostatic hyperplasia. Mapping the nuclear magnetic image volume data to a deformation field under an ultrasonic acquisition coordinate system, and deforming the preoperative nuclear magnetic image to an intra-operative ultrasonic space by using the deformation field to complete image registration; fusing the registered image with a stereoscopic vision system; the spatial depth of the surface of the target tissue is obtained from the endoscopic image so as to supplement navigation information; according to the utility model, the prostate deformation and probe posture change adaptive capacity in an operation is improved, the real-time visual closed-loop regulation and control capacity is improved, and the characteristics of small light spots, shallow heat diffusion, excellent hemostasis and the like of blue laser are combined, so that the vaporization and hemostasis precision in a tiny blood vessel dense area is ensured, and the problems of large tissue trauma and the like are avoided.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a pharmaceutical composition for treating benign prostatic hyperplasia and a preparation method thereof. The composition is prepared from the following medicinal materials in parts by weight: 6 to 8 parts of radix aconiti lateralis preparata, 3 to 5 parts of cortex cinnamomi, 10 to 15 parts of fructus alpiniae oxyphyllae, 10 to 15 parts of fructus psoraleae, 5 to 10 parts of semen myristicae, 5 to 10 parts of ground beeltle, 8 to 12 parts of spina gleditsiae, 10 to 15 parts of radix angelicae sinensis, 8 to 12 parts of radix linderae, 15 to 20 parts of radix rehmanniae praeparata, 10 to 15 parts of fructus corni, 8 to 12 parts of rhizoma anemarrhenae, 15 to 20 parts of radix scrophulariae, 8 to 12 parts of rhizoma alismatis, 5 to 10 parts of radix stephaniae tetrandrae and 10 to 15 parts of radix cyathulae. The invention provides the self-prepared medicine composition for treating the prostatic hyperplasia, the diseases of patients with the prostatic hyperplasia are remarkably improved through the synergistic effect of all the medicines in the composition, and a new traditional Chinese medicine treatment thought is provided for clinical treatment of the BPH disease. According to the traditional Chinese medicine composition, medicine pairs are increased or decreased on the basis of referring to a traditional Chinese medicine classic treatment compound, the unique traditional Chinese medicine composition is finally formed, and all the medicine pairs in the formula cooperate with one another and are indispensable.

A stent is disclosed that is configured to maintain patency of the prostatic urethra despite an enlarged prostate. The stent can include a handle that, in an undeflected position, is disposed outside of the flow path of the stent. When the handle is pulled, the handle can deflect to generally aligned with a central axis of the stent. A capture device is disclosed that includes a tapered tip to navigate a working channel of a delivery device and a hook that can capture the stent handle and be moved into a tube to retain the stent handle to facilitate maneuvering of the stent in and out of the working channel of the delivery device. A loading adapter with a tapered port is disclosed that can be disposed on the delivery device to distribute compressive forces applied by the port on the stent during loading into the working channel.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

An implantable biocompatible expander suitable for implantation into a urinary duct, comprises an elongated sinusoidal ring comprising at least two proximal prongs and at least two distal prongs, wherein the expander is resiliently deformable from a relaxed radially expanded orientation to a radially contracted orientation suitable for transluminal delivery through the urinary duct. The expander is configured to exert an outward radial force against a wall of the urinary duct when in-situ within the urinary duct. In particular, the expander is suitable for treatment of benign prostatic hyperplasia and configured for implantation into the prostatic urethra between, and substantially spanning the prostatic urethra between, the bladder neck and external sphincter.

A delivery device for positioning an implantable expander to a target location in a prostatic urethra. An implantable biocompatible expander suitable for implantation into a urinary duct is resiliently deformable from a relaxed radially expanded orientation to a radially contracted orientation suitable for transluminal delivery through the urinary duct. The expander may be configured to exert an outward radial force against a wall of the urinary duct when in-situ within the urinary duct. In particular, the expander is suitable for treatment of benign prostatic hyperplasia and configured for implantation into the prostatic urethra between, and substantially spanning the prostatic urethra between, the bladder neck and external sphincter.

An implantable biocompatible dilator (1) suitable for implantation in a urinary tract includes: an elongated sinusoidal ring having at least two proximal forks (7) and at least two distal forks (5), wherein the dilator can elastically deform from a relaxed radial expansion orientation to a radial contraction orientation, the radial contraction orientation being suitable for transluminal delivery through the urinary tract. The dilator is configured to apply radially outward forces to the urinary tract wall when in situ within the urinary tract. In particular, the dilator is suitable for treating benign prostatic hyperplasia and can be configured to be implanted and substantially cross the prostatic urethra between the bladder neck and the external sphincter.

The application discloses application of a reagent for detecting LRRN3 expression level in preparation of a benign prostatic hyperplasia diagnosis product. It is proved through cell function experiments and animal experiments that overexpression of the LRRN3 gene can inhibit the proliferation of prostate cells, block the cell cycle and promote cell apoptosis, thereby effectively inhibiting the prostatic hyperplasia. The discovery provides a new target and treatment strategy for the treatment of the prostatic hyperplasia, and provides a brand-new thought and method for the treatment of the prostatic hyperplasia. Based on the research results, a gene therapy drug taking the LRRN3 gene as a target can be further developed, for example, a lentivirus vector carrying the LRRN3 gene or other gene delivery systems are constructed and used for the treatment of the prostatic hyperplasia. In addition, the LRRN3 gene can be combined with other treatment methods to improve the treatment effect.

Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and / or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

The invention discloses 5 alpha-reductase degradation molecules as well as a preparation method and application thereof, four 5 alpha-reductase degradation molecules can realize thorough removal of zymoprotein by inducing proteasome-dependent degradation of 5 alpha-reductase instead of only inhibiting the activity of the 5 alpha-reductase, so that a more lasting treatment effect is obtained; under the condition of equal dosage, the effect of the 5 alpha-reductase degradation molecule on treating the benign prostatic hyperplasia is superior to that of the traditional inhibitor finasteride; the four kinds of 5 alpha-reductase degrading molecules can effectively degrade 5 alpha-reductase protein and remarkably inhibit development of benign prostatic hyperplasia, have good biological safety and provide new strategies and candidate drugs for treatment of diseases related to 5 alpha-reductase such as benign prostatic hyperplasia, prostatic cancer, androgenetic alopecia and acne.

The invention provides a medical functional coating, a preparation method and a implantation intervention medical device. The preparation method of the medical functional coating comprises the following steps: obtaining meso-porous silicon nanoparticles loaded with curcumin; adding the meso-porous silicon nanoparticles loaded with the curcumin into a solution of carboxymethyl chitosan and sodium alginate to form a gel solution of the meso-porous silicon nanoparticles loaded with the curcumin; providing a base material, and adsorbing the gel solution on the surface of the base material to form a coating capable of releasing curcumin; tissue regeneration after prostatic hyperplasia resection can be promoted, the antibacterial effect is achieved, the pain of a patient is relieved, and the treatment recovery period is shortened.

Computer-implemented methods for providing interactive electronic treatment assistance for benign prostatic hyperplasia and advanced prostate cancer are disclosed. The methods can include automatically sending, by a disease and disorder treatment device, an electronic pathway sign-up link to a smart mobile device. The method can include sending a plurality of inquiries about the BPH condition and / or the advanced prostate cancer condition, to the smart mobile device. The method can include receiving a plurality of patient responses from the smart mobile device. The method can include processing and storing the plurality of patient responses. The method can include providing, by the disease and disorder treatment device, patient education about various treatment therapies for advanced prostate cancer. The method can include automatically monitoring a patient having the advanced prostate cancer condition during the various treatment therapies. The method can include intervening with the various treatment therapies using the smart mobile device.

The utility model provides a prostate ultrasonic ablation device, and relates to the technical field of prostate treatment. The prostate ultrasonic ablation device comprises an ablation catheter, an ultrasonic transducer, an air bag, a mounting seat and a driving part, the ablation catheter is provided with a liquid inlet channel, a liquid outlet channel and a wire channel which are separated in the length direction of the ablation catheter. A mounting groove for mounting an ultrasonic transducer is formed in the side surface of one end of the ablation catheter; the ultrasonic transducer is fixedly arranged in the mounting groove; the air bag wraps one end of the ablation catheter, the air bag is provided with a notch at the position of the mounting groove, the liquid inlet channel and the liquid outlet channel are communicated with the interior of the air bag, the liquid inlet channel is used for supplying liquid into the air bag to expand the air bag, and the liquid outlet channel is used for discharging liquid in the air bag; the ablation catheter is rotatably supported on the mounting seat; the driving part is connected with the ablation catheter and can drive the ablation catheter to rotate relative to the mounting base. The prostatic hyperplasia ablation catheter can ablate prostatic hyperplasia tissues, and other tissues such as the urethral wall are not prone to being damaged.

The invention relates to application of pulsatilla saponin D in preparation of a medicine for preventing or treating human prostatic hyperplasia. The invention shows that the pulsatilla saponin D has an inhibition effect on human prostate cell WPMY-1, HPRF and BPH-1 cell strains, and can cause cell apoptosis to a certain extent, so that the pulsatilla saponin D shows the effect of preventing or treating prostatic hyperplasia.

The invention discloses a traditional Chinese medicine composition for treating uroschesis caused by benign prostatic hyperplasia and a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared by mixing leeches, radix semiaquilegiae, cortex phellodendri, rhizoma anemarrhenae, Chinese lobelia, polygonum cuspidatum, herba patriniae, dianthus superbus, cowherb seeds, lumbricus, pericarpium citri reticulatae viride and lindera aggregata and then decocting with water. According to the traditional Chinese medicine composition, treatment is carried out synergistically from the three aspects of rapid relieving of emergency symptoms, targeted treatment of pathologic roots and synchronous recovery of whole body metabolic balance, and the four-in-one comprehensive curative effect of diuretic, anti-male, anti-inflammatory and tissue repair is achieved; the traditional Chinese medicine composition is simple in preparation method, low in cost and wide in safety window, is applied to treatment of uroschesis caused by benign prostatic hyperplasia, and provides a family-friendly traditional Chinese medicine solution capable of replacing or being combined with existing chemical medicines for patients.

The invention relates to the technical field of biology, in particular to application of a prostate intermediate state cell and an inhibitor of the prostate intermediate state cell, and discloses application of the prostate intermediate state cell and an organ or tissue comprising the prostate intermediate state cell as a target in screening of drugs for treating prostatitis or prostatic hyperplasia. The prostate intermediate state cell inhibitor is applied to preparation of a medicine for treating prostatitis or benign prostatic hyperplasia; the inhibitor of the prostate intermediate state cells comprises one or more of a GRN signal channel inhibitor and a Sema4 signal channel agonist. The application provides a new therapeutic target for treatment of prostatitis or benign prostatic hyperplasia and drug screening, and provides a potential strategy for clinical treatment of prostatitis and benign prostatic hyperplasia.

The preparation method comprises the following steps: decocting urtica cannabina roots with water, carrying out macroporous resin, silica gel column chromatography and preparative HPLC (High Performance Liquid Chromatography) separation, and simultaneously preparing two kinds of high-purity urtica cannabina neoglycoside I (netleside I) and urtica cannabina neoglycoside II (netleside II) which have a remarkable prostatic hyperplasia resisting effect from urtica cannabina, thereby obtaining the urtica cannabina neoglycoside I (netleside I) and the urtica cannabina neoglycoside II (netleside II). The compound can be used for preparing anti-prostatic hyperplasia medicines; the method has the advantages of simplicity, rapidness, high purity, low production cost and the like.

Devices and systems are disclosed for managing and / or treating body tissues obstructing a hollow body lumen, including the prostatic lobe tissues obstructing the urethra, for example conditions including benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), benign prostatic obstruction (BPO) and associated lower urinary tract symptoms (LUTS). An implant is maintained in a constrained configuration within a distal portion of an elongated sheath so that is may be deployed by driving the implant with a pusher coaxially disposed within the sheath. An implant engaging element helps maintain control of the implant during deployment.

A 5α-reductase inhibitor contains saw palmetto extract and seaberry extract as an active ingredient in a synergistic compounding ratio, wherein the compounding ratio by weight of the saw palmetto extract and the seaberry extract is 3:1˜2. The 5α-reductase inhibitor containing the saw palmetto extract and seaberry extract or just the seaberry extract as a 5α-reductase inhibitor can be administered to the human body in order to inhibit 5α-reductase. The 5α-reductase inhibitor is useful as a prostate enlargement inhibitor, an androgenic alopecia inhibitor, and an acne prevention and amelioration agent. The 5α-reductase inhibitor can be part of a food or drink composition or a cosmetic composition.

A catheter for deploying an implantable expander in a urethra. An implantable biocompatible expander suitable for implantation into a urinary duct is resiliently deformable from a relaxed radially expanded orientation to a radially contracted orientation suitable for transluminal delivery through the urinary duct. The expander may be configured to exert an outward radial force against a wall of the urinary duct when in-situ within the urinary duct. In particular, the expander is suitable for treatment of benign prostatic hyperplasia and configured for implantation into the prostatic urethra between, and substantially spanning the prostatic urethra between, the bladder neck and external sphincter.

Some embodiments of the invention advantageously leverage the expansion of the prostatic urethra using adjustable lumen tension rings (ALTRs) of desired sizes to control and improve flow throughout the range of the urethra. As such, some embodiments include tension ring(s) or cylinders that sits either inside or outside the prostatic wall and is at least partially within the lumen and / or is partially or fully anchored, attached, adhered, or otherwise held in place with respect to the bladder or other locations within the urethra and / or elsewhere in the urethra. The expansion of the lumen can be pre-configured based on pre-operative metrology of the prostatic urethra to a customized and adjustable fit across the various zones within the urethra and based on the patient specific and evolving needs.

The application discloses an application of a prostate hyperplasia related marker in preparation of a product for detecting prostate hyperplasia, and the prostate hyperplasia related marker is at least one selected from MINP1, ACTBL and APOC4 proteins. In the technical scheme, MINP1, ACTBL and APOC4 are combined as a detection marker for prostate hyperplasia (BPH), so that the complementarity of the three in different stages of diseases can be fully exerted, and the comprehensive performance of the detection product is obviously improved. MINP1 and ACTBL participate in disease progression by regulating prostate cell proliferation and apoptosis, and APOC4 can present significant expression changes in blood cells of early BPH patients, so that BPH disease screening can be accurately performed. When the three are applied in cooperation, early screening of BPH can be realized, and the activity and severity of the lesion can be evaluated, so that a detection system covering the whole process of disease occurrence and development is formed, the limitation of a single marker in the diagnosis dimension is effectively made up, and the comprehensiveness and accuracy of BPH detection are greatly improved.

The present disclosure is directed to a method of treating overactive bladder symptoms in men with benign prostatic hyperplasia comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day.

The present invention relates to a powder composition consisting essentially of a lipid extract of Serenoa repens also called as Saw palmetto, polyethylene glycol, colloidal silicone dioxide, silicified microcrystalline cellulose and magnesium stearate. The said powder composition has a desirable flow property that provides easy capsule filling. The invention further relates to a process for the preparation of said powder composition and use thereof as medicament in the treatment of benign prostatic hyperplasia in adult men.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition for treating benign prostatic hyperplasia and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 5 to 10 parts of leech, 5 to 10 parts of centipede, 2 to 5 parts of earthworm, 2 to 5 parts of cicada slough, 2 to 5 parts of silkworm chrysalis, 2 to 5 parts of radix achyranthis bidentatae, 2 to 5 parts of pericarpium citri reticulatae, 2 to 5 parts of gecko and 5 to 10 parts of poria cocos. According to the traditional Chinese medicine composition, the formula is reasonably combined through monarch, minister, assistant and guide in traditional Chinese medicine, the medicine effect is maximized through the modern technology, and the effect of treating prostatic hyperplasia is achieved.